Analysis of the relation between adverse events and overall survival in patients treated with pembrolizumab as a first-line treatment for metastatic NSCLC

BACKGROUND: Many trials supported pembrolizumab as a first-line monotherapy to significantly improve overall survival (OS) in selected patients with previously untreated metastatic Non–Small Cell Lung Cancer (mNSCLC) and a PD-L1 TPS of ≥50% without EGFR/ALK mutations. The aim of this study was to re...

Descripción completa

Detalles Bibliográficos
Autores principales: Faoro, Lisa, Brusegan, Adriana, Russi, Alberto, Calderone, Vincenzo, Martelli, Alma, Marranconi, Ettore, Carpanese, Debora, Berti, Elena, Coppola, Marina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10184366/
https://www.ncbi.nlm.nih.gov/pubmed/37189193
http://dx.doi.org/10.1186/s40360-023-00663-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10184366/
https://www.ncbi.nlm.nih.gov/pubmed/37189193
http://dx.doi.org/10.1186/s40360-023-00663-0

Ejemplares similares